Compare NBP & BMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBP | BMMX |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.2M | 175.0M |
| IPO Year | 2019 | N/A |
| Metric | NBP | BMMX |
|---|---|---|
| Price | $1.43 | $3.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 672.5K | 98.4K |
| Earning Date | 08-20-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $3.13 |
| 52 Week High | $5.19 | $3.55 |
| Indicator | NBP | BMMX |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $1.44 | N/A |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 25.00 | 0.00 |
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.